All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Publication

Article

March 2, 2010

Pharmaceutical Technology

Pharmaceutical Technology-03-02-2010
Volume34
Issue 3

Baxter International's Shaun Newlon on Manufacturing Trends

The vice-president addresses shifts in process and more.

Shaun Newlon

PharmTech: Do you see a new industry trend emerging?

Newlon:

For solutions, I see a trend toward the production of more biologic agents, rather than conventional, chemically synthesized drugs, which translates to a major shift in manufacturing processes. With the higher value of biologic active ingredients, our manufacturing risk of loss increases. We have seen a strategic shift away from traditional economies of scale and high-speed lines toward small batch sizes with the goal of eliminating scrap and minimizing losses. Our manufacturing systems must be designed for more agility instead of our traditional focus on high run rates.

I also see a trend toward greater use of contract manufacturing services. Small biotech firms and large pharmaceutical companies are identifying manufacturing capability gaps or focusing internal assets on research activities, which spurs them to seek outside manufacturing as extensions of their own operations. Contract manufacturing plants must be customer-oriented entities that provide services and deliver products.

PharmTech:

What is the most common demand your clients are currently making of you?

Newlon:

One of our most regular client demands is the concept of available capacity on demand, especially in contract manufacturing. The desire for instant access and instant response has permeated our collective consciousness, and that extends to pharmaceutical manufacturing. We have to recognize immediacy as a customer expectation and design our contracting and planning systems accordingly. Although not always easy to manage, it's a necessary part of our successful business model.

Another request we get is to have greater flexibility in the quality agreements that define and govern our daily operating parameters. It is extremely challenging for two companies, each with different risk profiles, to be comfortable with the particulars of each other's quality systems and make them work in complementary fashions in a strict global regulatory environment. The good news is that people in our industry are passionate about acting responsibly to do what is right for patients.

Articles in this issue

i3_t-660528-1408626637817.jpg
In the Spotlight March 2010
i1-660522-1408626661127.jpg
Time for a Model Upgrade
Report from India
Report from India
frontimagePT-660521-1408626662870.jpg
Navigating the Global Pharmaceutical Supply Chain
i28-660531-1408626624434.jpg
Industry Pipeline
i9_t-660526-1408626644643.gif
Statistically Justifiable Visible Residue Limits

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Related Content
Advertisement
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 27th 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 27th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 27th 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 27th 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 27th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 27th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
Related Content
Advertisement
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 27th 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 27th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 27th 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 27th 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 27th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 27th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.